ATE333464T1 - Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika - Google Patents

Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika

Info

Publication number
ATE333464T1
ATE333464T1 AT98907779T AT98907779T ATE333464T1 AT E333464 T1 ATE333464 T1 AT E333464T1 AT 98907779 T AT98907779 T AT 98907779T AT 98907779 T AT98907779 T AT 98907779T AT E333464 T1 ATE333464 T1 AT E333464T1
Authority
AT
Austria
Prior art keywords
compositions
methods
antibiotics
combination
treating infections
Prior art date
Application number
AT98907779T
Other languages
German (de)
English (en)
Inventor
Janet R Fraser
Michael H P West
Patricia J Mcnicol
Original Assignee
Migenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/915,314 external-priority patent/US6180604B1/en
Application filed by Migenix Inc filed Critical Migenix Inc
Application granted granted Critical
Publication of ATE333464T1 publication Critical patent/ATE333464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT98907779T 1997-03-10 1998-03-10 Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika ATE333464T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4064997P 1997-03-10 1997-03-10
US08/915,314 US6180604B1 (en) 1996-08-21 1997-08-20 Compositions and methods for treating infections using analogues of indolicidin
US6009997P 1997-09-26 1997-09-26
US09/030,619 US6503881B2 (en) 1996-08-21 1998-02-25 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics

Publications (1)

Publication Number Publication Date
ATE333464T1 true ATE333464T1 (de) 2006-08-15

Family

ID=27487830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907779T ATE333464T1 (de) 1997-03-10 1998-03-10 Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika

Country Status (9)

Country Link
US (3) US6503881B2 (enExample)
EP (1) EP0966481B1 (enExample)
JP (1) JP2002544759A (enExample)
AT (1) ATE333464T1 (enExample)
AU (1) AU6604798A (enExample)
CA (1) CA2282807A1 (enExample)
DE (1) DE69835279T2 (enExample)
ES (1) ES2264198T3 (enExample)
WO (1) WO1998040401A2 (enExample)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6172185B1 (en) * 1998-05-20 2001-01-09 University Of British Columbia Antimicrobial cationic peptide derivatives of bactenecin
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
WO2000026344A1 (en) * 1998-10-30 2000-05-11 Interlink Biotechnologies Llc Peptides with enhanced stability to protease degradation
US6946261B1 (en) 1998-11-20 2005-09-20 Migenix Inc. Efficient methods for producing anti-microbial cationic peptides in host cells
WO2000046389A1 (en) * 1999-02-03 2000-08-10 Biogal Gyogyszergyar Rt Process for the preparation of pseudomonic acid a antibiotic by microbiological method
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US20030008369A1 (en) * 1999-03-03 2003-01-09 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases
US6835868B1 (en) 1999-03-17 2004-12-28 University Of Victoria Innovation And Development Corporation Transgenic plants expressing dermaseptin peptides providing broad spectrum resistance to pathogens
WO2000055337A1 (en) * 1999-03-17 2000-09-21 University Of Victoria Innovation And Development Corporation Transgenic plants that are resistant to a broad spectrum of pathogens
AU4941400A (en) * 1999-05-27 2001-01-22 Biocompatibles Limited Local drug delivery
US7015309B1 (en) 1999-06-23 2006-03-21 The Wistar Institute Of Anatomy And Biology Pyrrhocoricin-derived peptides, and methods of use thereof
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
WO2001045732A2 (en) * 1999-12-20 2001-06-28 Sa Majesté La Reine Du Chef Du Canada Agriculture Et Agroalimentaire Canada Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections
AU2795801A (en) * 2000-01-21 2001-07-31 Creighton University Biocidal molecules, macromolecular targets and methods of production and use
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US6632616B2 (en) * 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
US6777592B2 (en) 2000-04-14 2004-08-17 E.I. Du Pont Denemours And Company Arthropod defensins of Scolopendra canidens, Vaejovis carolinianus, and Argiope spp.
DE10030781A1 (de) * 2000-06-29 2002-01-17 Hassan Jomaa Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen
DE10042853A1 (de) * 2000-08-30 2002-04-25 Florian Lang Nachweis und Beeinflußung der Expression oder Funktion von CD95/CD95L bei Infektionen
CN1455673A (zh) * 2001-01-05 2003-11-12 凯敏工业公司 分离自至少部分通过其皮肤进行呼吸的生物体的细菌分离物和衍生自其中的生物活性提取物
WO2002064183A1 (en) * 2001-02-09 2002-08-22 Johnson & Johnson Vision Care, Inc. Biomedical devices with antimicrobial cationic peptide and protein coatings
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
CA2448547A1 (en) * 2001-06-21 2003-01-03 Biogal Gyogyszergyar Rt. Metabolic controlled fermentation process for pseudomonic acid production
AU2002317071B2 (en) * 2001-06-22 2008-01-31 The Hospital For Sick Children Antimicrobial peptides
US6835536B2 (en) * 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
JP4511173B2 (ja) 2001-08-24 2010-07-28 マイジェニックス インコーポレイテッド 抗菌性および抗炎症性ペプチド
KR100438416B1 (ko) * 2001-09-19 2004-07-02 학교법인조선대학교 Ｃａ－ｍａ 펩타이드의 아미노산 중 하나 또는 그 이상을치환하여 ＋ 전극과 소수성 영역이 증가된 신규한펩타이드 및 그를 포함하는 약학적 조성물
JP2005528883A (ja) * 2001-10-05 2005-09-29 ステリス インコーポレイテッド プリオシダル活性のためのインビトロモデル
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
WO2003065975A2 (en) 2001-12-28 2003-08-14 Biogal Gyogyszergyar Rt Processes for preparing crystalline and amorphous mupirocin calcium
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070021345A1 (en) * 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20030219854A1 (en) * 2002-03-21 2003-11-27 Micrologix Biotech Inc. Methods for producing modified anti-infective peptides
MXPA04009310A (es) * 2002-03-26 2005-01-25 Eastern Virginia Med School Suramin y derivados del mismo como microbicidas y contraceptivos.
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
FR2839311A1 (fr) * 2002-05-06 2003-11-07 Entomed Peptides antibacteriens, genes codant les peptides, vecteurs, organismes transformes, leurs preparations et les compositions les contenant
EP1360961A1 (en) * 2002-05-07 2003-11-12 AM-Pharma B.V. Use of antimicrobial peptides for potentiating the activity of antimicrobial agents
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
JP5118302B2 (ja) * 2002-10-29 2013-01-16 トランセイブ， インク． 抗感染剤の徐放
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
AU2003298937A1 (en) * 2002-12-06 2004-06-30 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004052308A2 (en) * 2002-12-10 2004-06-24 Biosynexus Incorporated Topical anti-infective formulations
DE10260537A1 (de) * 2002-12-21 2004-07-15 Kerek, Franz, Dr. Peptide mit hohem Cysteingehalt
CA2519429C (en) * 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US6989370B2 (en) * 2003-05-01 2006-01-24 The United States Of America As Represented By The Secretary Of Agriculture Bacteriocins and novel bacterial strains
SE0301431D0 (sv) 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2005006938A2 (en) * 2003-07-18 2005-01-27 Technion Research & Development Foundation Ltd. Anti-microbial medical implants and uses thereof
AU2003904225A0 (en) * 2003-08-08 2003-08-21 Ripetech Pty Limited Method for reducing precure during the curing of thermosetting resins
FR2858772A1 (fr) * 2003-08-14 2005-02-18 Diatos Composition anti bacterienne, plus particulierement contre les bacteries gram negatif, comprenant un peptide et un agent anti-bacterien avantageusement hydrophobe
EP1653989B1 (fr) * 2003-08-14 2009-07-15 Diatos Composition anti-bacterienne plus particulierement contre les bacteries gram negatif comprenent un peptide et un agent anti-bacterien avantageusement hydrophobe
US20050108047A1 (en) * 2003-11-19 2005-05-19 Vvii Newco 2003, Inc. Business methods for commercializing antibiotics
US7455840B2 (en) * 2003-11-19 2008-11-25 The Scripps Research Institute Compositions and methods to reduce mutagenesis
EP1732527A2 (en) * 2004-03-17 2006-12-20 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005090385A2 (en) * 2004-03-18 2005-09-29 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
KR20060123772A (ko) * 2004-06-01 2006-12-04 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 약물의 비결정형의 제조 방법
DK1828167T3 (da) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
PT1778720E (pt) 2004-08-18 2010-11-29 Novabiotics Ltd Péptidos antimicrobianos compreendendo um motivo com arginina e/ou lisina
US7700308B2 (en) * 2004-09-16 2010-04-20 University Of Washington Methods for determining susceptibility to dental caries
WO2006049580A1 (en) * 2004-11-04 2006-05-11 National University Of Singapore Anticoagulant peptides
EP1657249A1 (en) * 2004-11-10 2006-05-17 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Antibiotic drosocin derivatives
SE0402807D0 (sv) * 2004-11-17 2004-11-17 Dermagen Ab Novel antimicrobial peptides
EP1838331A4 (en) 2004-12-15 2012-12-26 Univ Colorado ANTIMICROBIAL PEPTIDES AND METHOD OF USE
BRPI0608464A2 (pt) * 2005-03-14 2010-01-05 Wyeth Corp composições de tigeciclina e processos de preparação
US20060286574A1 (en) * 2005-04-05 2006-12-21 The Scripps Research Institute & Achaogen, Inc. Compositions and methods for enhancing drug sensitivity and treating drug resistant infections and diseases
US7517852B2 (en) 2005-07-28 2009-04-14 Biosynexus Incorporated Compositions and methods for treating bacteria
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP3067046B1 (en) 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2007091958A1 (en) * 2006-02-10 2007-08-16 Dermagen Ab Novel antimicrobial peptides and use thereof
EP1987056B1 (en) * 2006-02-10 2012-07-25 Dermagen AB Novel antimicrobial peptides and use thereof
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
KR101487719B1 (ko) * 2006-05-16 2015-01-29 페르가뭄 아베 개선된 항미생물성 펩타이드
IL176303A0 (en) * 2006-06-14 2006-10-05 Shmuel Shraga Pharmaceutical composition for the treatment of otomycosis
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2076126A4 (en) * 2006-09-12 2011-12-28 Chaperone Technologies Inc NEW COMBINATIONS OF DNAK INHIBITORS WITH KNOWN ANTIBACTERIAL AGENTS
WO2008070116A2 (en) * 2006-12-04 2008-06-12 Concert, Llc Topical compositions for treatment of skin conditions
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
WO2008137717A1 (en) * 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
WO2009009156A2 (en) * 2007-07-06 2009-01-15 Laclede, Inc. Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages
DE102007036128A1 (de) * 2007-07-23 2009-02-12 Universität Leipzig Antibiotische Peptide
RU2010114018A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства
CA2698981A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
DE102008031284A1 (de) * 2008-07-02 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Neue Bekämpfungsmöglichkeit der Giardiose
DE102008031283A1 (de) * 2008-07-02 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Neue Bekämpfungsmöglichkeit von durch Trichomonadida hervorgerufenen Krankheiten
US20100008897A1 (en) * 2008-07-09 2010-01-14 Susan Daly Composition for providing a benefit to a keratin-containing substrate
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
US20100099614A1 (en) * 2008-10-06 2010-04-22 Hodges Robert S Antimicrobial Peptides and Methods of Use
EP2437770A4 (en) * 2009-06-05 2013-11-06 Univ Colorado Regents ANTIMICROBIAL PEPTIDES
BRPI1015203B1 (pt) * 2009-06-26 2021-06-01 Lysando Ag Proteína de fusão composta por uma endolisina e uma extensão de peptídeo anfifática, usos da mesma e composição farmacêutica que compreende a dita proteína
CA2764131C (en) 2009-06-26 2022-05-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Antimicrobial agents
TW201125577A (en) * 2009-12-02 2011-08-01 Novozymes As Use of defensins for treatment of infective endocarditis
JP5911503B2 (ja) 2010-11-15 2016-04-27 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． アミロイド線維形成関連状態を処置するためのジペプチドアナログ
WO2012097258A2 (en) * 2011-01-15 2012-07-19 The Regents Of The University Of California Formulations for the prevention and treatment of wolbachia-related disease
EP4331675A3 (en) 2012-05-21 2024-05-29 Insmed Incorporated Systems for treating pulmonary infections
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
AU2013355391B2 (en) * 2012-12-03 2017-08-03 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US9624283B2 (en) 2013-04-16 2017-04-18 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
KR102137941B1 (ko) 2013-05-10 2020-07-29 아카데미슈 지켄후이스 라이덴 항균 펩티드
KR101550965B1 (ko) * 2013-07-31 2015-09-07 씨제이제일제당 (주) 초고압을 이용한 야채류 식품의 제조방법
US10059752B2 (en) * 2013-10-14 2018-08-28 University Of Houston System Esculentin 1a derivatives and uses thereof
US10751440B2 (en) * 2013-10-14 2020-08-25 University Of Houston System Esculentin 1a derivatives and uses thereof
CN105828828A (zh) * 2013-10-31 2016-08-03 和黄生物膜医疗解决方案有限公司 肽在抗生素抗性中的用途
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CN106535877A (zh) 2014-05-15 2017-03-22 英斯梅德股份有限公司 用于治疗肺部非结核性分枝杆菌感染的方法
WO2015188140A1 (en) 2014-06-06 2015-12-10 The Curators Of The University Of Missouri Enhancement of antibiotic efficacy
CN107106525B (zh) 2014-10-24 2021-03-19 红山生物医药有限公司 用于抑制单链rna病毒复制的治疗
ES2740273T3 (es) * 2015-02-22 2020-02-05 Omnix Medical Ltd Péptidos antimicrobianos
KR101773390B1 (ko) * 2015-05-08 2017-08-31 동아인코팜 주식회사 여드름 개선용 화장료 조성물
MX2018002586A (es) 2015-09-01 2020-11-24 First Wave Bio Inc Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
MX2018010198A (es) 2016-02-25 2019-06-12 Applied Biological Laboratories Inc Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
ES2842443T3 (es) 2016-02-26 2021-07-14 Debiopharm Int Sa Medicamento para el tratamiento de infecciones del pie diabético
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
ITUA20163612A1 (it) 2016-05-19 2017-11-19 Icf Srl Nuovi composti attivi contro microorganismi patogeni
WO2017223098A1 (en) 2016-06-21 2017-12-28 The Curators Of The University Of Missouri Bis-amino acid based compound and use thereof
CN106589135B (zh) * 2016-11-25 2018-08-28 东北农业大学 一种靶向抗菌肽及其制备方法和应用
EP3573465A4 (en) 2017-01-24 2020-11-04 Flagship Pioneering Innovations V, Inc. PROCESSES AND RELATED COMPOSITIONS FOR THE MANUFACTURE OF FEEDS AND FEEDS
US20200060286A1 (en) 2017-01-24 2020-02-27 Flagship Pioneering Innovations V, Inc. Compositions and related methods for controlling vector-borne diseases
AU2018213284B2 (en) 2017-01-24 2024-03-28 Flagship Pioneering Innovations V, Inc. Compositions and related methods for agriculture
UA126575C2 (uk) 2017-01-24 2022-11-02 Флегшіп Пайонірінг Інновейшнз V, Інк. Композиція і спосіб контролю захворювань, що передаються переносниками
US20190387748A1 (en) * 2017-01-24 2019-12-26 Flagship Pioneering Innovations V, Inc. Compositions and related methods for agriculture
EP3585171A4 (en) 2017-02-24 2020-08-26 Flagship Pioneering Innovations V, Inc. COMPOSITIONS AND ASSOCIATED PROCESSES FOR THE MODULATION OF ENDOSYMBIONTES
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN108434438B (zh) * 2018-06-22 2020-08-25 安徽科技学院 抗菌肽在制备治疗幽门螺杆菌病的药物中的用途以及药物组合物
IL285204B2 (en) 2019-02-14 2025-02-01 Debiopharm Int Sa Formulation of apavicin, method for its preparation
EP3982975A1 (en) 2019-06-14 2022-04-20 Debiopharm International SA Afabicin for use for treating bacterial infections involving biofilm
US11471433B1 (en) 2019-08-01 2022-10-18 Flagship Pioneering Innovations V, Inc. Postbiotic compositions and related methods for agriculture
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20240041805A1 (en) * 2020-09-17 2024-02-08 Board Of Regents, The University Of Texas System Pharmaceutical compositions of niclosamide and a protein

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
US5547939A (en) 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5324716A (en) 1991-06-14 1994-06-28 Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
WO1995008344A1 (en) 1993-09-22 1995-03-30 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
AU703192B2 (en) 1994-01-14 1999-03-18 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US5877274A (en) 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
WO1997008199A2 (en) 1995-08-23 1997-03-06 University Of British Columbia Antimicrobial cationic peptides and methods of screening for the same
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
WO1999043357A1 (en) 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers

Also Published As

Publication number Publication date
EP0966481A2 (en) 1999-12-29
AU6604798A (en) 1998-09-29
DE69835279T2 (de) 2007-07-12
WO1998040401A3 (en) 1998-12-17
US6503881B2 (en) 2003-01-07
US20030232750A1 (en) 2003-12-18
JP2002544759A (ja) 2002-12-24
HK1025103A1 (en) 2000-11-03
CA2282807A1 (en) 1998-09-17
DE69835279D1 (de) 2006-08-31
EP0966481B1 (en) 2006-07-19
US20020035061A1 (en) 2002-03-21
ES2264198T3 (es) 2006-12-16
US20110150780A1 (en) 2011-06-23
WO1998040401A2 (en) 1998-09-17
US7309759B2 (en) 2007-12-18

Similar Documents

Publication Publication Date Title
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
DE69732871D1 (de) Basisches Protein Zusammensetzung, basisches Peptid Zusammensetzung und deren Verwendung
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
TW224055B (enExample)
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
WO1993023434A3 (en) Bpi-immunoglobulin fusion proteins
GR3019901T3 (en) Osteoinductive pharmaceutical formulations
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
CA2131565A1 (en) Organopolysiloxanes Containing Hydrophilic Groups
ATE408685T1 (de) Antimikrobielle peptide, abstammend von ubiquicidin
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
PT938329E (pt) Composicao de tlp imunogenica
PL351376A1 (en) Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE69534738D1 (de) Leukocyten-aktivierender Faktor
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties